KORU Medical Systems, Inc. (KRMD) Earnings
KORU Medical Systems, Inc. is expected to report next earnings on August 5, 2026 (in NaN days), with a consensus EPS estimate of $-0.02. KRMD has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise +8.3% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $-0.02 | $-0.02 | +0.0% | $12M | +4.3% |
| Mar 12, 2026 | $-0.02 | $-0.01 | +50.0% | $11M | -0.0% |
| Nov 12, 2025 | $-0.03 | $-0.02 | +33.3% | $10M | -4.6% |
| May 7, 2025 | $-0.02 | $-0.03 | -50.0% | $10M | +1.9% |
| Mar 12, 2025 | $-0.03 | $-0.03 | +0.0% | $9M | -0.3% |
| May 1, 2024 | $-0.01 | $-0.02 | -47.4% | $8M | — |
| Mar 13, 2024 | $-0.02 | $-0.02 | -25.0% | $7M | -5.1% |
| May 4, 2023 | $-0.04 | $-0.05 | -25.0% | $7M | -0.6% |
| Mar 8, 2023 | $-0.05 | $-0.04 | +20.0% | $7M | -0.5% |
| Nov 9, 2022 | $-0.05 | $-0.03 | +40.0% | $8M | — |
| Aug 3, 2022 | $-0.06 | $-0.06 | +0.0% | $7M | — |
| May 4, 2022 | $-0.06 | $-0.05 | +16.7% | $6M | +0.0% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Linda Tharby announces this is her final earnings call as CEO, with Adam set to succeed her on July 1st. Q1 2026 was a record start with robust revenue growth. Key highlights include domestic KORU's 12% y-o-y growth, international core's 35% y-o-y growth, and progress in the non-IG pipeline. Adam elaborates on the three-pillar strategy: safeguarding and expanding the domestic core business, international expansion, and enabling more drugs to reach patients. Tom then delves into financial results, gross margin details, cash flow dynamics, and reaffirms the full-year guidance.
Guidance
The company is reiterating its full-year 2026 guidance. Revenue is projected to range from $47.5 million to $50 million, representing a 15% to 22% growth. Gross margin is expected to fall within the 61% to 63% range, with positive adjusted EBITDA and cash flow throughout the year. Q2 is anticipated to be the quarter with the highest cash usage due to annual one-time bonus payouts, but positive cash flow is expected in the latter half of the year. Geopolitical risks associated with the Middle East are factored into the guidance.
Segment performance
Q1 2026 generated $11.8 million in revenue, marking a 22% year-over-year growth. Domestically, the KORU segment saw a 12% year-over-year increase, fueled by new patient diagnosis starts in legacy accounts and competitive conversions within the SCIG market. Internationally, the core segment grew by 35% due to pre-filled syringe conversions in Europe and strong distributor orders in new markets. Additionally, PSP revenues soared by 166% compared to the prior year period, driven by higher clinical trial product revenues from advancing pharma collaborations.
Risks & headwinds
Geopolitical risks related to the Middle East pose a concern, specifically with caution regarding the Middle East distributor due to geopolitical uncertainties in the region. Additionally, monitoring of oil prices and supply chain impacts stemming from the Middle East situation is ongoing, though no material impacts have been observed thus far.
Analyst Q&A
Q: Rationale for maintaining top-line guidance despite Q1's strong performance and the updated cadence for the year.
A: Adam states there's strong momentum, but variability exists in vial to pre-fill syringe conversions in Europe, and the guidance remains confident for now as the year unfolds further.
Q: Update on oncology-related discussions.
A: The oncology opportunity is a $40 million market that's expected to grow to over $120 million in five years. FESGO was filed at the end of last year and is under active FDA review, with other oncology drugs also in active discussions.
Q: Insights on SEIG volume growth and international markets.
A: In the U.S., Coru outpaced the SCIG market with growth, and internationally, progress is being made across 5 mentioned markets.
Q: Measures to mitigate Mideast fuel surcharges and price increases.
A: Coru is closely monitoring oil prices and the supply chain, but no material impacts have been seen so far.
Q: Status of the next-gen pump 510K submission.
A: The Freedom 360 pump is in the final stages of development, undergoing design verification testing, and is expected to have regulatory filings submitted in the U.S. and Europe during the second half of 2026